News Column

SPECTRUM PHARMACEUTICALS INC FILES (8-K) Disclosing Regulation FD Disclosure, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events, Financial Statements and Exhibits

July 3, 2014



Item 7.01 Regulation FD Disclosure.

On July 3, 2014, Spectrum Pharmaceuticals, Inc. (the "Company") received notification from the U.S. Food and Drug Administration ("FDA") of their early action granting accelerated approval of the Company's New Drug Application ("NDA") for Beleodaq™ (belinostat) for Injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL"). This indication was approved by FDA under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Important Beleodaq safety information is included in the attachment hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial

Obligation or an Obligation under an Off-Balance Sheet Arrangement.



As previously announced, in 2010 the Company licensed the oncology drug asset Beleodaq (belinostat) for Injection from TopoTarget A/S ("TopoTarget") through a License and Collaboration Agreement (the "Agreement") for all uses in North America and India, with an option for China (as is defined in the Agreement). In connection with the transaction, TopoTarget remained eligible to receive contingent consideration upon the achievement of certain regulatory and sales milestones. As a result of the satisfaction of a NDA approval milestone, described above, pursuant to the Agreement, the Company becomes obligated to pay TopoTarget $25 million in cash.

Item 8.01 Other Events.

On July 3, 2014, the Company received further notifications from the FDA regarding the post marketing requirements ("PMRs") for each of Beleodaq and Folotyn®. With respect to Folotyn, the two previous Folotyn PMRs for the Phase 3 PTCL trial and the Phase 3 cutaneous T-cell lymphoma ("CTCL") trial have been released by FDA. The new PMRs for Beleodaq and Folotyn include a main study that evaluates the comparative efficacy and safety of Folotyn when used in combination with the treatment regimen cyclophosphamide/ vincristine/doxorubicin/prednisone ("CHOP") or the combination of Beleodaq plus CHOP, versus CHOP alone for the initial therapy of patients with PTCL. Important safety information for Beleodaq and Folotyn is included in the attachment hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. Exhibit No. Description 99.1 Important Safety Information for BELEODAQ (belinostat) for Injection and FOLOTYN (pralatrexate injection) 2



--------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters